Clinical Trials Logo

Filter by:
NCT ID: NCT06127628 Recruiting - Anesthesia Clinical Trials

Effectiveness of Ultrasound-guided Scalp Block for Supratentorial Craniotomy

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Pain management in patients undergoing neurosurgery is a very important issue. The effectiveness of USG-guided scalp blocks for pain management in craniotomy surgery is currently not known. The purpose of this clinical trial is to evaluate the effectiveness of ultrasound-guided scalp block when performed in patients who undergo supratentorial craniotomies.

NCT ID: NCT06122558 Recruiting - Clinical trials for Constipation - Functional

Efficacy of Probiotic Against Functional Constipation

Start date: October 27, 2023
Phase: Phase 2
Study type: Interventional

This project aims to study the benefits of probiotic in modulating gut microbiota and treating functional constipation in patients aged 18-81.

NCT ID: NCT06120491 Recruiting - Clinical trials for Metastatic Castration-Sensitive Prostate Cancer

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

EvoPAR-PR01
Start date: November 21, 2023
Phase: Phase 3
Study type: Interventional

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

NCT ID: NCT06120140 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

COCOON
Start date: February 16, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib.

NCT ID: NCT06118281 Not yet recruiting - Cardiovascular Risk Clinical Trials

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

ARTEMIS
Start date: June 25, 2024
Phase: Phase 3
Study type: Interventional

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

NCT ID: NCT06112379 Recruiting - Breast Cancer Clinical Trials

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Start date: November 14, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

NCT ID: NCT06111872 Recruiting - Pancreatic Cancer Clinical Trials

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

Start date: July 18, 2023
Phase: Phase 2
Study type: Interventional

Does Ketamine-Midazolam have a better efficacy and safety profile compared to Midazolam - Pethidine in Endoscopic Retrograde Cholangiopancreatography (ERCP)?

NCT ID: NCT06102915 Completed - Clinical trials for Coronary Artery Disease

Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting

Start date: August 1, 2023
Phase:
Study type: Observational

The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.

NCT ID: NCT06100900 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Start date: October 24, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in participants with paroxysmal nocturnal hemoglobinuria (PNH). Approximately 15 participants will be enrolled in this study. Participants may receive treatment for up to 24 weeks.

NCT ID: NCT06096389 Recruiting - Muscle Soreness Clinical Trials

Effect of Acheta Domesticus Supplementation on Post-Exercise Muscle Recovery in Recreationally Active Male

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the effect of house cricket (Acheta domesticus) supplementation for strength recovery in recreationally active males. The main question[s] it aims to answer are: whether house cricket powder could improve strength recovery and whether house cricket powder could be an alternative to commonly used protein supplement. Participants will do exercise (100 drop jumps) to induce fatigue and then they will consume either isocaloric carbohydrate, whey protein isolate or defatted house cricket powder for 4 days. Their strength will be measured every 24 hours for 4 days in order to observe the recovery. Researcher will compare house cricket powder with isocaloric carbohydrate to see if the strength recovery is faster in house cricket powder group Researcher will compare house cricket powder with whey protein isolate to see if the strength recovery is comparable.